Article

Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder.

Pediatric Psychopharmacology Research Clinic, Massachusetts General Hospital, Boston, Massachusetts 02114, and New York University School of Medicine, New York, NY, USA.
Biological Psychiatry (Impact Factor: 9.47). 06/2007; 61(12):1380-7. DOI: 10.1016/j.biopsych.2006.07.032
Source: PubMed

ABSTRACT This multicenter, randomized, fixed-dose, double-blind, placebo-controlled study evaluated efficacy of extended-release dexmethylphenidate (d-MPH-ER) in adults with attention-deficit/hyperactivity disorder (ADHD).
Randomized adults with ADHD (n=221) received once-daily d-MPH-ER 20 mg, 30 mg, or 40 mg or placebo for 5 weeks. The primary efficacy variable was change from baseline to final visit in DSM-IV ADHD Rating Scale (ADHD-RS) total score. Secondary efficacy parameters included the proportion of patients with improvement>or=30% in ADHD-RS total score and final scores on Clinical Global Impressions-Improvement (CGI-I) scale.
Of 218 evaluable patients, 184 completed the study. All d-MPH-ER doses were significantly superior to placebo in improving ADHD-RS total scores. Placebo scores improved by 7.9; d-MPH-ER, 20 mg, improved by 13.7 (p=.006); d-MPH-ER, 30 mg, improved by 13.4 (p=.012); and d-MPH-ER, 40 mg, improved by 16.9 (p<.001). Overall distribution of CGI-I ratings at final visit was significantly better with each d-MPH-ER dosage than with placebo. There were no unexpected safety or tolerability concerns, based on experience with racemic methylphenidate (MPH) in adults and dexmethylphenidate (d-MPH) in children.
Once-daily d-MPH-ER at 20 mg, 30 mg, or 40 mg is a safe and effective treatment for adults with ADHD.

0 Bookmarks
 · 
72 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In the management of attention-deficit hyperactivity disorder (ADHD) in adults it is important to recognize that individual patients respond to a wide range of methylphenidate doses. Studies with methylphenidate modified release long acting (MPH-LA) in children have reported the need for treatment optimization for improved outcomes. We report the results from a post hoc analysis of a 5-week dose optimization phase from a large randomized, placebo-controlled, multicenter 40-week study (9-week double-blind dose confirmation phase, 5-week open-label dose optimization phase, and 26-week double-blind maintenance of effect phase).
    Clinical Drug Investigation 07/2014; · 1.70 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by symptoms of inattention, hyperactivity, and impulsivity that cause functional impairment. Recent research indicates that symptoms persist into adulthood in the majority of cases, with prevalence estimates of approximately 5% in the school age population and 2.5%-4% in the adult population. Although students with ADHD are at greater risk for academic underachievement and psychosocial problems, increasing numbers of students with ADHD are graduating from high school and pursuing higher education. Stimulant medications are considered the first line of pharmacotherapy for individuals with ADHD, including college students. Although preliminary evidence indicates that prescription stimulants are safe and effective for college students with ADHD when used as prescribed, very few controlled studies have been conducted concerning the efficacy of prescription stimulants with college students. In addition, misuse of prescription stimulants has become a serious problem on college campuses across the US and has been recently documented in other countries as well. The purpose of the present systematic review was to investigate the efficacy of prescription stimulants for adolescents and young adults with ADHD and the nonmedical use and misuse of prescription stimulants. Results revealed that both prostimulant and stimulant medications, including lisdexamfetamine dimesylate, methylphenidate, amphetamines, and mixed-amphetamine salts, are effective at reducing ADHD symptoms in adolescents and adults with ADHD. Findings also suggest that individuals with ADHD may have higher rates of stimulant misuse than individuals without the disorder, and characteristics such as sex, race, use of illicit drugs, and academic performance are associated with misuse of stimulant medications. Results also indicate that individuals both with and without ADHD are more likely to misuse short-acting agents than long-acting agents. These findings have implications for intervention, prevention, and future research.
    Psychology Research and Behavior Management 01/2014; 7:223-49.
  • [Show abstract] [Hide abstract]
    ABSTRACT: El objetivo del presente estudio fue valorar la asociación entre los déficits de la función ejecutiva (DFE) y la respuesta al tratamiento con metilfenidato en adultos con trastorno por déficit de atención con hiperactividad (TDAH). Efectuamos un estudio aleatorizado, controlado con placebo, con un diseño de grupos paralelos y de 6 semanas de duración entre adultos con TDAH diagnosticados según los criterios del DSM-IV. Para el índice psicométrico de la función ejecutiva se utilizaron exámenes neuropsicológicos estandarizados. Evaluamos las conductas reflejas de DFE utilizando el cuestionario Behavior Rating Inventory of Executive Function, versión para el adulto (BRIEF-A). Se incluyeron para el análisis los individuos con parámetros disponibles del funcionamiento ejecutivo (tratados con MPH OROS, n = 40; tratados con placebo n = 47). No hubo una diferencia en el porcentaje de individuos que completaron la fase i del ensayo sobre eficacia aguda, de 6 semanas de duración (100% [n = 40] frente al 98% [n = 46]; p = 0,4). Al concluir el período de observación de la fase i la dosis diaria media de MPH OROS era de 84,6 ± 31,6 mg (1,04 ± 0,29 mg/kg) y la de placebo de 100,5 ± 21,9 mg (1,20 ± 0,11 mg/kg) (p = 0,0007). En función de los exámenes neuropsicológicos realizados en la valoración basal, se consideró que el 40% de individuos con TDAH (n = 35/87) experimentaba DFE pero, en la escala clínica BRIEF-A, en el 93% de individuos (n = 81) se identificaron ≥ 2 puntuaciones T > 65. Sin embargo, con independencia de la definición utilizada, los DFE no tuvieron una influencia en la respuesta clínica al tratamiento con MPH OROS. El presente ensayo clínico aleatorizado reveló que los déficit de la función ejecutiva no moderan la respuesta al metilfenidato y los parámetros de los déficit de la función ejecutiva no se asocian a la respuesta al tratamiento con MPH OROS.
    Psiquiatría Biológica. 01/2012; 19(1):1-8.